Clinical Trials
Clinical trials are essential to helping researchers find new and better ways to treat disease. By testing medicines in development, these studies help determine whether a potential therapy is safe and effective. None of this is possible without the partnership of patients who choose to participate.
Important: Budoprutug and CLYM116 are investigational therapies and have not yet been approved by any regulatory agency. Only your doctor can determine if a clinical trial may be right for you.
Budoprutug in primary membranous nephropathy (pMN)
ID: NCT07096843
Phase: Phase 2
Description: This Phase 2, open-label, multicenter study evaluates the safety, pharmacodynamics, and preliminary efficacy of three intravenous dose regimens of budoprutug in adult subjects with primary membranous nephropathy (PMN) who are anti-PLA2R antibody positive and have persistent proteinuria despite optimized RAAS inhibition.
Budoprutug in immune thrombocytopenia (ITP)
ID: NCT07043946
Phase: Phase 1b/2a
Description: This Phase 1b/2a, open-label, sequential-cohort, dose escalation and expansion study will evaluate the safety, tolerability, PK, PD, and preliminary clinical effectiveness of budoprutug in subjects with ITP.
Budoprutug in systemic lupus erythematosus (SLE)
ID: NCT07011043
Phase: Phase 1b
Description: This Phase 1b, open-label study will evaluate budoprutug administered as a single intravenous infusion in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE.
Budoprutug subcutaneous vs. IV injection in healthy volunteers
ID: NCT07090655
Phase: Phase 1
Description: This Phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of budoprutug administered subcutaneously (SC) in adult normal healthy volunteers (NHVs).